Liquidia Corporation
LQDA
Kedudukan dalam Saham
#4848
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Harga Saham
$34.12
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.05B
Perubahan (1 hari)
-0.67%
Perubahan (1 tahun)
39.61%
Negara
US
Perdagangan Liquidia Corporation (LQDA)
Kategori
Healthcare
Sejarah hasil dividen untuk Liquidia Corporation (LQDA)
Hasil dividen (TTM) bagi Liquidia Corporation (simbol saham: LQDA) pada 2023-12-31 adalah: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Liquidia Corporation (LQDA) dari 2016 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 1.57% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
